AveXis Inc (AVXS) Receives Average Recommendation of “Buy” from Analysts

Shares of AveXis Inc (NASDAQ:AVXS) have been given an average rating of “Buy” by the nine ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $93.83.

Several analysts have commented on the stock. Chardan Capital set a $103.00 price target on shares of AveXis and gave the stock a “buy” rating in a research note on Sunday. Jefferies Group LLC reiterated a “buy” rating and issued a $92.00 price target on shares of AveXis in a research note on Wednesday, April 19th. Citigroup Inc. assumed coverage on shares of AveXis in a research note on Tuesday, May 23rd. They issued a “buy” rating and a $90.00 price target on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $95.00 price target on shares of AveXis in a research note on Friday. Finally, Goldman Sachs Group, Inc. (The) boosted their price target on shares of AveXis from $91.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, March 17th.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $81.39, for a total value of $144,874.20. Following the sale, the vice president now owns 1,780 shares in the company, valued at approximately $144,874.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 5,341 shares of company stock worth $406,682.

Hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors boosted its stake in shares of AveXis by 9.0% in the first quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock valued at $262,000 after buying an additional 284 shares in the last quarter. American International Group Inc. boosted its stake in shares of AveXis by 26.7% in the first quarter. American International Group Inc. now owns 3,521 shares of the company’s stock valued at $268,000 after buying an additional 742 shares in the last quarter. Swiss National Bank boosted its stake in shares of AveXis by 3.0% in the first quarter. Swiss National Bank now owns 27,400 shares of the company’s stock valued at $2,083,000 after buying an additional 800 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of AveXis by 2.6% in the first quarter. Teachers Advisors LLC now owns 54,217 shares of the company’s stock valued at $4,122,000 after buying an additional 1,387 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of AveXis during the first quarter valued at about $117,000. Institutional investors and hedge funds own 90.47% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “AveXis Inc (AVXS) Receives Average Recommendation of “Buy” from Analysts” was originally reported by Stock Observer and is the property of of Stock Observer. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.thestockobserver.com/2017/06/20/avexis-inc-avxs-receives-average-recommendation-of-buy-from-analysts.html.

Shares of AveXis (NASDAQ:AVXS) traded down 2.076% during midday trading on Tuesday, hitting $70.535. The company had a trading volume of 330,673 shares. The stock has a 50 day moving average price of $74.27 and a 200 day moving average price of $65.34. AveXis has a 1-year low of $31.55 and a 1-year high of $85.98. The firm’s market capitalization is $1.96 billion.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, May 11th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.94) by $0.13. During the same period last year, the firm posted ($1.24) EPS. On average, equities analysts anticipate that AveXis will post ($4.56) EPS for the current fiscal year.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply